Connection
Shitiz Sriwastava to Humans
This is a "connection" page, showing publications Shitiz Sriwastava has written about Humans.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.900 |
|
|
|
-
Amatya S, Khan E, Kagzi Y, Akkus S, Gupta R, Hansen N, Wen S, Jaiswal S, Sriwastava S. Disease characteristics of NMOSD and their relationship with disease burden: Observations from a large single-center cohort. J Neurol Sci. 2024 Dec 15; 467:123311.
Score: 0.038
-
Sriwastava S, Elkhooly M, Amatya S, Shrestha K, Kagzi Y, Bhatia D, Gupta R, Jaiswal S, Lisak RP. Recent advances in the treatment of primary and secondary progressive Multiple Sclerosis. J Neuroimmunol. 2024 05 15; 390:578315.
Score: 0.036
-
Akkus S, Elkhooly M, Amatya S, Shrestha K, Sharma K, Kagzi Y, Khan E, Gupta R, Piquet AL, Jaiswal S, Wen S, Tapia M, Samant R, Sista SR, Sriwastava S. Autoimmune and paraneoplastic neurological disorders: A review of relevant neuroimaging findings. J Neurol Sci. 2023 11 15; 454:120830.
Score: 0.036
-
Tolaymat S, Sharma K, Kagzi Y, Sriwastava S. Anti-CD20 monoclonal antibody (mAb) therapy and colitis: A case series and review. Mult Scler Relat Disord. 2023 Jul; 75:104763.
Score: 0.035
-
Sharma K, Tolaymat S, Yu H, Elkhooly M, Jaiswal S, Jena A, Kakara M, Sriwastava S. Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: A review. J Neurol Sci. 2022 12 15; 443:120459.
Score: 0.033
-
Peterson S, Jalil A, Beard K, Kakara M, Sriwastava S. Updates on efficacy and safety outcomes of new and emerging disease modifying therapies and stem cell therapy for Multiple Sclerosis: A review. Mult Scler Relat Disord. 2022 Dec; 68:104125.
Score: 0.033
-
Feizi P, Sharma K, Pasham SR, Nirwan L, Joseph J, Jaiswal S, Sriwastava S. Central nervous system (CNS) inflammatory demyelinating diseases (IDDs) associated with COVID-19: A case series and review. J Neuroimmunol. 2022 10 15; 371:577939.
Score: 0.033
-
Yu H, Wu H, R S, Kaur A, Pasham SR, Upadhaya R, Sriwastava S. Single-center experience on progressive multifocal leukoencephalopathy (PML) cases, neuroimaging relevance, and management at West Virginia University (WVU). J Med Virol. 2022 08; 94(8):4015-4022.
Score: 0.032
-
Sharma K, Chaudhary D, Beard K, Srivastava S, Khalid SH, Sriwastava S. A comprehensive review of varicella-zoster virus, herpes simplex virus and cryptococcal infections associated with sphingosine-1-phosphate receptor modulators in multiple sclerosis patients. Mult Scler Relat Disord. 2022 Mar; 59:103675.
Score: 0.032
-
Khan E, Shrestha AK, Elkhooly M, Wilson H, Ebbert M, Srivastava S, Wen S, Rollins S, Sriwastava S. CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review. J Neurol Sci. 2022 Jan 15; 432:120089.
Score: 0.031
-
Sriwastava S, Khan E, Khalid SH, Kaur A, Feizi P. Progressive multifocal leukoencephalopathy in an immunocompetent patient: A case report and review of literature. J Med Virol. 2022 06; 94(6):2860-2869.
Score: 0.031
-
Sriwastava S, Chaudhary D, Srivastava S, Beard K, Bai X, Wen S, Khalid SH, Lisak RP. Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature. J Neurol. 2022 Mar; 269(3):1678-1687.
Score: 0.031
-
Beard K, Sriwastava S. Insight in booster COVID-19 vaccine and disease modifying therapy in multiple sclerosis. J Neurol Sci. 2021 Nov 15; 430:120034.
Score: 0.031
-
Sriwastava S, Kataria S, Srivastava S, Kazemlou S, Gao S, Wen S, Saber H, Tripathi R, Sheikh Z, Peterson S, Gwinn R, Bernitsas E. Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis. J Neuroimmunol. 2021 11 15; 360:577721.
Score: 0.031
-
Khan E, Shrestha AK, Colantonio MA, Liberio RN, Sriwastava S. Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature. J Neurol. 2022 Mar; 269(3):1121-1132.
Score: 0.031
-
Sriwastava S, Lisak RP. Acetylcholine receptor antibodies in a patient with sensory neuropathy. J Neuroimmunol. 2021 10 15; 359:577692.
Score: 0.031
-
Moreno-Escobar MC, Feizi P, Podury S, Tandon M, Munir B, Alvi M, Adcock A, Sriwastava S. Acute cerebellitis following SARS-CoV-2 infection: A case report and review of the literature. J Med Virol. 2021 Dec; 93(12):6818-6821.
Score: 0.031
-
Podury S, Khan E, Tandon M, Jaiswal S, Sriwastava S. Evolution of our understanding of MS-COVID-19 interactions and concerns for vaccination. J Clin Neurosci. 2021 Aug; 90:132-134.
Score: 0.030
-
Sriwastava S, Tandon M, Podury S, Prasad A, Wen S, Guthrie G, Kakara M, Jaiswal S, Subedi R, Elkhooly M, Lisak RP. COVID-19 and neuroinflammation: a literature review of relevant neuroimaging and CSF markers in central nervous system inflammatory disorders from SARS-COV2. J Neurol. 2021 Dec; 268(12):4448-4478.
Score: 0.030
-
Wen S, Prasad A, Freeland K, Podury S, Patel J, Subedi R, Khan E, Tandon M, Kataria S, Kimble W, Sriwastava S. Clinical Characteristics and Outcomes of COVID-19 in West Virginia. Viruses. 2021 05 05; 13(5).
Score: 0.030
-
Frey J, Kramer J, Castellani R, Sriwastava S. Clinical Reasoning: A 47-Year-Old With Headache, Vertigo, and Double Vision. Neurology. 2021 08 03; 97(5):e535-e539.
Score: 0.030
-
Moreno-Escobar MC, Kataria S, Khan E, Subedi R, Tandon M, Peshwe K, Kramer J, Niaze F, Sriwastava S. Acute transverse myelitis with Dysautonomia following SARS-CoV-2 infection: A case report and review of literature. J Neuroimmunol. 2021 04 15; 353:577523.
Score: 0.030
-
Tandon M, Kataria S, Patel J, Mehta TR, Daimee M, Patel V, Prasad A, Chowdhary AA, Jaiswal S, Sriwastava S. A Comprehensive Systematic Review of CSF analysis that defines Neurological Manifestations of COVID-19. Int J Infect Dis. 2021 Mar; 104:390-397.
Score: 0.029
-
Sriwastava S, Kataria S, Tandon M, Patel J, Patel R, Jowkar A, Daimee M, Bernitsas E, Jaiswal P, Lisak RP. Guillain Barr? Syndrome and its variants as a manifestation of COVID-19: A systematic review of case reports and case series. J Neurol Sci. 2021 01 15; 420:117263.
Score: 0.029
-
Sriwastava S, Tandon M, Kataria S, Daimee M, Sultan S. New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review. J Neurol. 2021 Aug; 268(8):2690-2696.
Score: 0.029
-
Prasad A, Kataria S, Srivastava S, Lakhani DA, Sriwastava S. Multiple embolic stroke on magnetic resonance imaging of the brain in a COVID-19 case with persistent encephalopathy. Clin Imaging. 2021 Jan; 69:285-288.
Score: 0.029
-
Sriwastava S, Yarraguntla K, Zutshi D, Basha MM, Bernitsas E, Marawar R. Relevance of cerebrospinal fluid findings in patients with multiple sclerosis and seizures. J Neurol Sci. 2019 Nov 15; 406:116482.
Score: 0.027
-
Sriwastava S, Desai A, Yuliati A, Watson CR, Sivaswamy L. A Child With a Hoarse Cry and Intracranial Calcification. Pediatr Neurol. 2018 10; 87:78-79.
Score: 0.025
-
Elkhooly M, Rube J, Srivastava S, Sriwastava S, Lisak R, Bernitsas E. Neuromyelitis Optica in a Young Woman With Tuberous Sclerosis: Is There an Association? J Investig Med High Impact Case Rep. 2022 Jan-Dec; 10:23247096221117808.
Score: 0.008
-
Marcus C, Feizi P, Hogg J, Summerfield H, Castellani R, Sriwastava S, Marano GD. Imaging in Differentiating Cerebral Toxoplasmosis and Primary CNS Lymphoma With Special Focus on FDG PET/CT. AJR Am J Roentgenol. 2021 01; 216(1):157-164.
Score: 0.007
-
Yarraguntla K, Seraji-Bozorgzad N, Lichtman-Mikol S, Razmjou S, Bao F, Sriwastava S, Santiago-Martinez C, Khan O, Bernitsas E. Multiple Sclerosis Fatigue: A Longitudinal Structural MRI and Diffusion Tensor Imaging Study. J Neuroimaging. 2018 11; 28(6):650-655.
Score: 0.006
-
Desai A, Sriwastava S, Gadgeel SM, Lisak RP. New onset myasthenia gravis in a patient with non small cell lung cancer treated with lorlatinib a novel anti-cancer agent. J Neurol Sci. 2018 09 15; 392:100-101.
Score: 0.006
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|